Skip to main content
Erschienen in: Journal of Cardiothoracic Surgery 1/2010

Open Access 01.12.2010 | Review

Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature

verfasst von: Wobbe Bouma, Theo J Klinkenberg, Iwan CC van der Horst, Inez J Wijdh-den Hamer, Michiel E Erasmus, Marc Bijl, Albert JH Suurmeijer, Felix Zijlstra, Massimo A Mariani

Erschienen in: Journal of Cardiothoracic Surgery | Ausgabe 1/2010

Abstract

Libman-Sacks endocarditis of the mitral valve was first described by Libman and Sacks in 1924. Currently, the sterile verrucous vegetative lesions seen in Libman-Sacks endocarditis are regarded as a cardiac manifestation of both systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS). Although typically mild and asymptomatic, complications of Libman-Sacks endocarditis may include superimposed bacterial endocarditis, thromboembolic events, and severe valvular regurgitation and/or stenosis requiring surgery. In this study we report two cases of mitral valve repair and two cases of mitral valve replacement for mitral regurgitation (MR) caused by Libman-Sacks endocarditis. In addition, we provide a systematic review of the English literature on mitral valve surgery for MR caused by Libman-Sacks endocarditis. This report shows that mitral valve repair is feasible and effective in young patients with relatively stable SLE and/or APS and only localized mitral valve abnormalities caused by Libman-Sacks endocarditis. Both clinical and echocardiographic follow-up after repair show excellent mid- and long-term results.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1749-8090-5-13) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

WB collected the data, systematically reviewed the literature, and wrote the manuscript. TK was lead surgeon. TK, IH, IJH, ME, MB, AS, FZ, and MM participated in the design of the manuscript and they revised and critically reviewed the manuscript. All authors read and approved the final manuscript.
Abkürzungen
aPLs
antiphospholipid antibodies
APS
antiphospholipid syndrome
LS
Libman-Sacks
LV
left ventricle
MR
mitral regurgitation
MS
mitral stenosis
MVP
mitral valve plasty
MVR
mitral valve replacement
NBTE
non-bacterial thrombotic endocarditis
SLE
systemic lupus erythematosus
TEE
transesophageal echocardiography
TTE
transthoracic echocardiography.

Introduction

In 1924 Libman and Sacks first described four cases of non-bacterial verrucous vegetative endocarditis [1]. The sterile verrucous lesions of Libman-Sacks (LS) endocarditis (Fig 1) show a clear predisposition for the mitral and aortic valves and are nowadays seen as both a cardiac manifestation of systemic lupus erythematosus (SLE) and, more recently, of the antiphospholipid syndrome (APS) [25].
SLE is an autoimmune disorder resulting in multi-organ inflammatory damage. Over the last decades with prolonged survival and improvement in diagnostic techniques, particularly in echocardiography, cardiac disease associated with SLE has become more apparent [6, 7]. A recent echocardiographic study in patients with SLE revealed that LS vegetations can be found in approximately 11% of patients with SLE [8]. In 63% of these patients with vegetations the mitral valve was involved [8]. Earlier echocardiographic studies reported a higher prevalence of LS vegetations in patients with SLE, ranging from 53% to 74% [9, 10].
Antiphospholipid syndrome (APS) has been defined as venous or arterial thrombosis, recurrent fetal loss, or thrombocytopenia accompanied by increased levels of antiphospholipid antibodies (aPLs) (i.e anticardiolipin antibodies and the lupus anticoagulant) [1114]. This syndrome can be either primary or secondary to an underlying condition (most commonly SLE) [1114]. An echocardiographic study in patients with primary APS showed that approximately one third of these patients have LS valvular lesions [4]. SLE is frequently accompanied by the presence of aPLs, which is associated with a higher prevalence of valvular abnormalities in SLE patients [5, 15].
Although typically mild and asymptomatic, LS endocarditis can lead to serious complications, including superimposed bacterial endocarditis, thromboembolic events, such as stroke and transient ischaemic attacks, and severe valvular regurgitation and/or stenosis requiring surgery.
The literature on mitral valve surgery for mitral regurgitation (MR) caused by LS endocarditis is comparatively sparse. In this study we report two cases of mitral valve repair and two cases of mitral valve replacement for MR caused by LS endocarditis. In addition, we provide a systematic review of the English literature on mitral valve surgery for MR caused by LS endocarditis.

Case Reports

We analyzed our institution's mitral valve surgery database and found four patients who underwent mitral valve surgery for MR caused by LS endocarditis in the period 1995-2008.

Patient 1

A 49-year-old Caucasian man presented at our institution with SLE that had been diagnosed originally in August 1996. Manifestations of his disease included arthritis, a rash on sun-exposed skin, and skin lesions resembling urticaria. Laboratory findings are shown in Table 1. A skin biopsy revealed urticarial vasculitis. There was no evidence of cerebral or renal involevement. His therapy for SLE required long-term plaquenil and prednisone. In September 1997 the patient was admitted with progressive exertional dyspnoea, cardiac decompensation, and a blowing systolic murmur at the apex radiating to the left axilla. Transthoracic (TTE) and transesophageal echocardiography (TEE) revealed severe MR with thickened mitral valve leaflets and a small vegetation on the posterior mitral valve leaflet. Repeated blood cultures were negative and there was no other evidence of infective endocarditis. The patient was recompensated with diuretics and discharged. Echocardiographic follow-up over the following months revealed a rapid increase in left ventricular diameters and normal left ventricular (LV) function. Results of cardiac catherization are shown in Table 1. The patient underwent mitral valve repair in March 1998. Intraoperative inspection showed slightly thickened, but otherwise surprisingly normal leaflets. A small perforation was found in the P2 section of the posterior leaflet. Preoperatively a small vegetation was found near this location. Although rare and more often seen in infectious endocarditis, leaflet perforation in LS endocarditis has been reported before [16]. This patient's history did not reveal any documented thromboembolic events. A quadrangular resection of the P2 section of the posterior mitral valve leaflet was performed, followed by implantation of a 32 mm Carpentier-Edwards Classic annuloplasty ring. Microscopic examination of the excised mitral valve segment revealed myxoid degeneration and no evident signs of inflammation. Although evidence of LS endocarditis could not be found microscopically, the diagnosis was made based on the clinical features, laboratory findings, and echocardiographic appearance. The patient's recovery from surgery was uneventful, and he was discharged on the seventh postoperative day. Echocardiographic follow-up revealed stable slight MR from April 1998 through January 2009. When last seen in March 2009, the patient was doing well, except for a mild degree of dyspnoea.
Table 1
Preoperative baseline characteristics of four patients with MR caused by LS endocarditis
Patient
1
2
3
4
Gender
Male
Male
Female
Female
Age (years)
49
56
28
22
SLE/APS
SLE
SLE
APS
APS
Years of SLE/APS
1.5
4
1
0.5
Steroids
yes
yes
no
no
Valve Lesion
MR
MR
MR
MR
NYHA class
IV
I
III
I
Echocardiography
    
   -MR grade
4+
4+
4+
2+
   -LV function
normal
normal
normal
normal
Cardiac Catheterization
    
   -Coronary artery disease
no
no
no
NA
   -PAP (mmHg) (N: 15-30/3-12 mmHg)
34/6
41/18
32/21
NA
   -PCWP (mmHg) (N: 1-10 mmHg)
10
18
21
NA
   -LVEDP (mmHg) (N: 3-12 mmHg)
10
18
19
NA
   -Cardiac Output (L/min/m2) (N: 2.6-4.2 L/min/m2)
2.74
3.20
4.30
NA
Laboratory tests
    
   -Repeated blood cultures
neg
neg
neg
neg
   -CRP (mg/l) (N: 0-5 mg/l)
38
60
3
34
   -White blood cell count (×109/l) (N: 4.0-10.0 × 109/l)
4.6
3.8
6.8
8.9
   -Thrombocyte count (×109/l) (N: 150-300 × 109/l)
258
249
105
114
   -Lupus anticoagulant (N: neg)
NA
NA
pos
pos
   -Anti-cardiolipin Ab (IgG) (U/ml) (N: <10 U/ml)
<10
25
>100
53
   -Anti-cardiolipin Ab (IgM) (U/ml) (N: <10 U/ml)
<10
<10
<10
<10
   -Complement C3 (g/l) (N: 0.90-1.80 g/l)
0.39
0.77
1.19
1.57
   -Complement C4 (g/l) (N: 0.10-0.40 g/l)
0.13
0.19
0.31
0.39
   -Anti-Nuclear Antibody (ANA) titer (N: <20)
320
>640
40
40
   -Anti-ds-DNA Ab (Farr-assay) (U/ml) (N: <10 U/ml)
11
154
<3
5
   -Extractable Nuclear Antigens (ENA) (N: neg)
NA
neg
neg
neg
Ab, antibodies; APS, anti-phospholipid syndrome; CRP, C-reactive protein; ds-DNA, double stranded DNA; LS, Libman-Sacks; LV(EDP), left ventricular (end-diastolic pressure); MR, mitral regurgitation; N, normal values; NA, not available; NYHA, New-York heart association; PAP, pulmonary artery pressure; PCPW, pulmonary capillary wedge pressure; SLE, systemic lupus erythematosus

Patient 2

A 56-year-old Caucasian man presented at our institution with severe SLE that had been diagnosed originally in July 2003. Manifestations of his disease included arthritis, pericarditis, and pleuritis without any evidence of skin, cerebral or renal involvement. Laboratory findings are shown in Table 1. His therapy for SLE required long-term prednisone, plaquenil and azathioprine. On routine examination in 2006 the patient appeared to have a blowing systolic murmur at the apex radiating to the left axilla. Transthoracic echocardiography (TTE) revealed mitral valve thickening with focal vegetations and severe MR. Repeated blood cultures were negative and there was no other evidence of infectious endocarditis. Results of cardiac catheterization are shown in Table 1. The patient underwent mitral valve replacement with a 31 mm St. Jude mechanical prosthesis in October 2007. The excised mitral valve was thickened and fibrotic with focal vegetations. Microscopic pathologic examination of the excised mitral valve revealed fibrosis, neovascularization, and vegetations with fibrin-platelet thrombi and evident inflammatory cell infiltration (Fig 2A,B). LS endocarditis of the mitral valve was confirmed. The patient's recovery from surgery was uneventful, and he was discharged on the seventh postoperative day. Echocardiographic follow-up revealed no MR. When last seen in April 2009, the patient was doing well.

Patient 3

A 28-year-old Caucasian woman was referred to our institution in October 2006 with arthralgias and intermittent haemoptysis. She had a missed abortion earlier that year, when she was nine weeks pregnant. Laboratory findings are shown in Table 1. The patient was diagnosed with primary APS. In November 2006 she presented with exertional dyspnoea and a blowing systolic murmur at the apex radiating to the left axilla. Transthoracic echocardiography (TTE) revealed mitral valve leaflet thickening with small vegetations on the edges of both leaflets (Fig 3A,B) and severe MR with backflow into the pulmonary veins (Fig 3C). Repeated blood cultures were negative and there was no other evidence of infectious endocarditis. Results of cardiac catheterization are shown in Table 1. The patient underwent mitral valve replacement in October 2007. Intraoperative inspection revealed thickened and fibrotic mitral valve leaflets with focal vegetations (Fig 3D,E). Therefore, mitral valve repair was not considered possible and the mitral valve was replaced with a 31 mm St. Jude mechanical prosthesis. Microscopic pathologic examination of the excised mitral valve revealed myxoid and hyaline degeneration, fibrosis, and vegetations with fibrin-platelet thrombi and evident inflammatory cell infiltration (Fig 2C,D). LS endocarditis of the mitral valve was confirmed. The patient's recovery from surgery was uneventful, and she was discharged on the seventh postoperative day. Echocardiographic follow-up revealed no MR. When last seen in June 2009, the patient was doing well.

Patient 4

A 22-year-old Hispanic woman with a history of hypothyreoidism was referred to our institution in October 2007 after a transient ischemic attack of the right cerebral hemisphere with temporary left hemiplegia. Routine trans-thoracic echocardiography revealed a tumor with a diameter of approximately 1 cm on the atrial side of the posterior mitral valve leaflet (Fig 4A,B) as the source of this thrombo-embolic event. In addition, a normal LV function and moderate (grade 2+) MR was found (Fig 4C). Repeated blood cultures were negative and there was no other evidence of infectious endocarditis. Based on her history and the echocardiographic appearance of the tumor the initial working diagnosis was papillary fibroelastoma. Laboratory findings are shown in Table 1. The patient was diagnosed with primary APS. Subsequently, LS endocarditis of the mitral valve was considered as an alternative diagnosis. To prevent future thrombo-embolic events the patient was accepted for mitral valve surgery. Cardiac catherization was not performed. The patient underwent mitral valve repair in March 2008. Intraoperative inspection showed a large verrucous tumor on the atrial side of the P2 section of the posterior mitral valve leaflet (Fig 4D). A quadrangular resection of the P2 section of the posterior mitral valve leaflet was performed (Fig 4E), followed by implantation of a 28 mm Cosgrove-Edwards annuloplasty ring. Microscopic examination of the excised mitral valve segment revealed myxoid degeneration and large vegetations with fibrin-platelet thrombi, but without an evident inflammatory infiltrate (Fig 2E,F). The initial working diagnosis of papillary fibroelastoma could not be confirmed on microscopic examination. A definite diagnosis of LS endocarditis was made. The patient's recovery from surgery was uneventful, and she was discharged on the seventh postoperative day. Echocardiographic follow-up after 1.5 years revealed no recurrence of MR. When last seen in September 2009, the patient was doing well.

Systematic Review

We systematically reviewed the literature on mitral valve surgery for (isolated) MR caused by (SLE and/or APS related) LS endocarditis (Table 2). We performed separate Medline (PubMed), EMBASE, and Cochrane database queries with the following text and keywords: "libman-sacks endocarditis, mitral", "antiphospholipid syndrome, mitral", and "non-bacterial thrombotic endocarditis, mitral". All papers were considered irrespective of their quality or the journal in which they were published. We then used strict criteria. Titles and abstracts were screened and relevant papers were selected. All papers with a case report or a series of case reports on mitral valve surgery for (isolated) MR caused by LS endocarditis were included. Reports not written in English were excluded, as well as reports without a clear description of MR etiology and/or mitral valve pathology. In addition, cases of mitral valve surgery for mitral stenosis (MS) (4 cases) or combined MR and MS (11 cases) caused by LS endocarditis were excluded. Although these exclusions may be seen as a limitation, we believe it is a particular strength of this study, since it generated a "clean" cohort of patients that underwent mitral valve surgery for (isolated) MR caused by Libman-Sacks endocarditis.
Table 2
Systematic review of the English literature on mitral valve surgery for (isolated) MR caused by Libman-Sacks endocarditisa
Reference
Year
published
Gender/
Age (years)
SLE and/
or APS
Years of SLE
and/or APS
Steroids
MR
gradeb
MVR/MVP
Surgical procedure
Follow-up
Myerowitz et al [48]
1974
F/22
SLE
3
yes
4+
MVR
Reis-Hancock porcine bioprosthesis
alive 2 months post-op
Murray et al [49]
1975
F/43
SLE
2
yes
4+
MVR
Beall Surgitoul mechanical prosthesis
alive 6 months post-op
Paget et al [50]
1975
F/18
SLE
4
yes
4+
MVR
Porcine xenograft (bioprosthesis)
alive 4 months post-op
Kinney et al [51]
1980
F/27
SLE
0.3
no
4+
MVR
Hancock porcine bioprosthesis
NR
Rawsthorne et al [52]
1981
M/51
SLE
21
no
4+
MVRc
Hancock porcine bioprosthesis
NR
Brennan et al
[53]
1983
F/20
SLE
2
yes
4+
MVR
Björk-Shiley mechanical prosthesis
CVA 17 months post-op
Rozman et al
[54]
1986
M/43
SLE
2
yes
NR
MVR
Starr-Edwards mechanical prosthesis
alive 4 years post-op
Moynihan et al
[55]
1988
F/54
SLE
2
yes
4+
MVRc
Carpentier-Edwards porcine bioprosthesis
alive 26 months post-op
Straaton et al
[56]
1988
F/22
SLE
<1
no
4+
MVRd
Carpentier-Edwards heterograft (bioprosthesis)
NR
  
F/67
SLE
10
yes
2+/3+
MVRc
St. Jude mechanical prosthesis
died intraoperatively
Ferraris et al
[57]
1990
M/34
SLE
9
yes
4+
MVR
Carpentier-Edwards bioprosthesis
alive 2.5 years post-op
Alvarez et al
[58]
1994
F/42
APS
1
no
2+/3+
MVR
Medtronic Hall mechanical prosthesis
NR
Kalangos et al
[40]
1995
F/28
SLE
0.5
yes
4+
MVP
Resection of the prolapsed posterior commissure and restoration with an autologous pericardial patch; sliding plasty of the anterior leaflet; transposition of secondary chordae to the commisure; Carpentier- Edwards annuloplasty ring
no MR recurrence 1 year post-op
Chauvaud et al [41]
1995
F/17
SLE
5
yes
4+
MVP
Posterior leaflet enlargement with pericardial
patch and Carpentier-Edwards annuloplasty ring
MS 6 months post-op
due to calcification
       
redo MVR
Cryopreserved homograft
alive 1 year post-op
Shahian et al
[59]
1995
F/29
APS
0
yes
4+
MVR
St. Jude mechanical prosthesis
alive 2 years post-op
Gordon et al
[46]
1996
M/37
SLE, APS
>2
yes
1+/2+
MVRc
Carpentier-Edwards porcine bioprosthesis
recurrent A-V fistula
       
redo MVR
Carpentier-Edwards porcine bioprosthesis
died 1 month post-op
Morin et al [33]
1996
F/40
SLE
12
yes
4+
MVR
St. Jude mechanical prosthesis
alive 2 weeks post-op
East et al [60]
2000
F/51
SLE, APS
NR
no
4+
MVRe
not further specified
NR
  
F/49
SLE, APS
7
yes
4+
MVR
not further specified
NR
Hakim et al [42]
2001
F/23
SLE
8
yes
4+
MVR
St. Jude mechanical prosthesis
alive >1 year post-op
  
F/54
SLE
7
yes
4+
MVPf
not further specified
MR 29 months post-op
       
redo MVR
St. Jude mechanical prosthesis
alive >5 years post-op
  
F/64
SLE
2
yes
4+
MVPe
Quadrangular resection of the posterior leaflet and Duran annuloplasty ring
alive >3 years post-op
Kato et al [43]
2001
F/52
APS
NR
no
4+
MVP
Kay's annuloplasty and Cosgrove annuloplasty ring
alive 3 months post-op
Mottram et al
[23]
2002
M/50
APS
0
no
0/1+
MVP
Removal of two mitral valve masses
alive 9 weeks post-op
da Silva et al
[47]
2003
F/54
SLE, APS
13
yes
4+
MVR
Bioprosthesis (not further specified)
bioprosth. thrombosis and death 9 months post-op
Schneider et al [44]
2003
M/23
SLE
NR
NR
4+
MVP
not further specified
NR
Georghiou et al [61]
2003
F/44
SLE
1
yes
3+
MVRc,d
St. Jude mechanical prosthesis
alive 6 months post-op
Bordin et al [62]
2003
F/57
SLE, APS
3
NR
4+
MVR
Mechanical prosthesis (not further specified)
MI 2 days post-op
Berkun et al
[63]
2004
F/48
APS
NR
yes
3+/4+
MVR
Carbomedics mechanical prosthesis
MR 90 months post-op
       
redo MVR
not further specified
died 6 months post-op
  
F/73
APS
NR
yes
3+/4+
MVR
Hancock porcine bioprosthesis
died 13 months post-op
  
F/47
APS
NR
yes
3+/4+
MVRc
Carbomedics mechanical prosthesis
splenic embolus 3 and CVA 10 months post-op
alive 42 months post-op
  
F/38
SLE, APS
NR
yes
3+/4+
MVR
Carbomedics mechanical prosthesis
alive 32 months post-op
  
F/51
SLE, APS
NR
yes
3+/4+
MVR
Carbomedics mechanical prosthesis
alive 33 months post-op
Fernández et al [45]
2005
F/36
SLE
8
NR
4+
MVP
not further specified
mild MR 1 year post-op
Taguchi et al
[24]
2006
F/34
SLE
9
yes
0/1+
MVP
Resection of A3 and attached chordae (en-bloc);
restoration of the anterior leaflet; 4 PTFE neochordae
no MR recurrence 6 months post-op
Einav et al [64]
2007
F/28
SLE, APS
4.5
yes
4+
MVRc,d
Mechanical prosthesis (not further specified)
NR
Takayama et al [16]
2008
M/58
SLE, APS
0
no
3+/4+
MVP
Valvuloplasty and annuloplasty (not further specified)
NR
Bouma et al
2010
M/49
SLE
1.5
yes
4+
MVP
Quadrangular resection of the posterior stable trace MR leaflet (P2) and Carpentier-Edwards annuloplasty ring
stable trace MR 11 years post-op
  
M/56
SLE
4
yes
4+
MVR
St. Jude mechanical prosthesis
alive >1.5 years post-op
  
F/28
APS
1
no
4+
MVR
St. Jude mechanical prosthesis
alive >1.5 years post-op
  
F/22
APS
0.5
no
2+
MVP
Quadrangular resection of the posterior leaflet (P2) and Cosgrove-Edwards annuloplasty ring
no MR recurrence 1.5 years post-op
A-V, atrioventricular; APS, antiphospholipid syndrome; CVA, cerebrovascular accident; F, female; M, male; MI, myocardial infarction; MR, mitral regurgitation; MS, mitral stenosis;MVP, mitral valve plasty; MVR, mitral valve repair; NR, not reported; PTFE, polytetrafluorethylene; SLE, systemic lupus erythematosus
areports not written in English or reports of mitral valve surgery in patients with SLE and/or APS without a description of MR etiology and mitral valve pathology were excluded; cases of MS (n = 4) or combined MR/MS (n = 11) caused by Libman-Sacks endocarditis were also excluded
bMR severity grading: 0, no or trace MR; 1+, mild MR; 2+, moderate MR; 3+, moderate-to-severe MR; 4+, severe MR
cincluding aortic valve replacement (AVR)
dincluding tricuspid valve plasty (TVP)
eincluding CABG
fincluding aortic valve plasty (AVP)

Discussion

Nowadays LS endocarditis is seen as a cardiac manifestation of both SLE and APS [25]. LS endocarditis is usually typically mild and asymptomatic, but can lead to serious complications, such as superimposed bacterial endocarditis, thromboembolic events, and valvular regurgitation and/or stenosis requiring surgery. The mitral valve is most commonly affected [8, 10]. The presence of APLs in patients with SLE is related to a higher prevalence of valvular abnormalities [5, 15], which suggests a possible role for APLs in the pathogenesis.

Pathogenesis

At this point the exact pathogenesis of LS endocarditis is still unclear. The initial insult to the valve, which causes endothelial damage and elicits the pathogenetic sequence of events, has not yet been identified. However, LS endocarditis has been assumed to involve the formation of fibrin-platelet thrombi on the altered valve, the organization of which leads to valve fibrosis, edema, diffuse thickening, mild inflammatory changes, valve distortion, scarring, and subsequent valvular dysfunction [5, 7, 1719]. Both valve thickening and formation of vegetations represent different stages of the same pathological proces [5]. Immunologic injury has been postulated as a possible initiating insult, since immunofluorescent microscopy revealed deposition of immunoglobulins and complement on affected valves [5, 19]. Rather than playing a more direct pathogenetic role, aPLs are thought to promote thrombus formation on the endothelium of valves already compromised by immune complex deposition, leading to further valvular damage and inflammation [5, 8, 15, 17, 18, 20, 21].

Microscopy

Valvular LS lesions are microscopically characterized by fibrin deposits at various stages of fibroblastic organization, neovascularization, occasional haematoxylin bodies, and by a variable extent of inflammation with mononuclear cell infiltration [6, 7]. Valvular lesions change over time [10] and the end-stage or healed form of LS verrucous endocarditis is a fibrous plaque, sometimes with focal calcification [5]. If the lesions are extensive enough, their healing may be accompanied by marked scarring, thickening, and deformity of the valve [5].

LS Endocarditis versus Non-Bacterial Thrombotic Endocarditis (NBTE)

Microscopically, the mitral valve vegetations seen in SLE are distinct from those seen in (primary) APS. A rather remarkable difference is the absence (or minimal extent) of inflammatory cell infiltration in (primary) APS [5, 22]. To emphasize this difference some authors prefer to use the term NBTE for the valve lesions seen in primary APS instead of the term LS endocarditis. However, others (including the authors of this study) prefer to use the term LS endocarditis, because the two underlying diseases are both auto-immune phenomena, are often interrelated (APS secondary to SLE), and probably share a (partially) similar pathologic pathway in causing valve lesions.

Differentiation from infective endocarditis and intracardiac tumors

Due to its asymptomatic nature establishing a diagnosis of LS endocarditis can be rather difficult. This is further complicated by the fact that the condition can mimick intracardiac tumors [2325] and bacterial endocarditis ("pseudoinfective" endocarditis) [26] or may coexist with (superimposed) bacterial endocarditis (also known as "double-decker" endocarditis) [7, 26, 27].
The modified Duke criteria can be useful in helping differentiate between true infective endocarditis and LS endocarditis [28]. Helpful laboratory markers in distinguishing infective endocarditis from LS endocarditis are the white blood cell count (elevated in infective endocarditis and often decreased in LS endocarditis), C-reactive protein levels (elevated in infective endocarditis and relatively low in LS endocarditis), aPL levels (normal in infective endocarditis and moderate to high in LS endocarditis), and (repeated) blood cultures (positive in infective endocarditis and negative in LS endocarditis) [21, 29]. Echocardiographically, LS vegetations appear as valve masses of varying size and shape with irregular borders and echodensity, they are firmly attached to the valve surface and exhibit no independent motion [8]. Contrary to the vegetations of infective endocarditis, which typically exhibit independent motion [30].
As previously demonstrated [2325] and as we showed in patient 4, differentiation from intracardiac tumors can also be difficult. Although LS vegetations are usually typically sessile, wartlike, and small, varying from pinhead size to 3-4 mm [5], they can become rather large making them difficult to distinguish (echocardiographically) from a typical mitral valve tumor such as papillary fibroelastoma. On echocardiography papillary fibroelastoma usually arise via a pedicle from mitral valve tissue or adjacent endocardium, and have a characteristic frond-like appearance [31]. A remarkable feature that LS vegetations do not posses.
Recently, a prospective randomized controlled study showed that TEE was superior to TTE in diagnosing LS endocarditis [32]. Nevertheless, establishing the diagnosis remains challenging.

Treatment with corticosteroids and anticoagulation

Corticosteroids do not prevent LS endocarditis, but they facilitate healing of LS lesions over time by decreasing the amount of inflammation [5, 3335]. However, they can increase fibrosis and scarring, ultimately worsening valvular damage and dysfunction [5, 3335]. Nonetheless, appropriate steroid therapy to control SLE disease activity is important.
The risk of thrombo-embolic events (mainly stroke and transient ischaemic attacks) is increased in LS endocarditis [8]. Current therapeutic guidelines for APS include thrombo-embolic prevention with long-term anticoagulation [5]. In addition, patients with LS endocarditis who have suffered a thrombo-embolic event are recommended to be on lifelong anticoagulation for prevention of future thrombo-embolic events [5]. Moreover, implantation of a mechanical valve requires anticoagulation and atrial fibrillation is frequently a concomitant condition necessitating anticoagulation in patients with severe MR. In other words, lifelong anticoagulation can often not be avoided in these patients.

Mitral valve surgery

In most patients hemodynamically important valvular dysfunction can be controlled with conservative treatment (i.e immunosuppression, anticoagulation, endocarditis profylaxis, and specific heart failure treatment including ACE-inhibitors, beta-blockers, diuretics) [5, 36, 37]. However, if severe symptomatic valvular dysfunction persists mitral valve surgery may be required.

Valve repair versus replacement and valve selection

In contemporary cardiac surgery mitral valve repair has become the mainstay of surgical treatment for most causes of MR. Particularly, in the last two decades there has been a gradual shift from mitral valve replacement to mitral valve repair for MR caused by a broad range of etiologies. Several general advantages of mitral valve repair over replacement include a lower operative mortality rate, higher survival rates, better maintainance of left ventricular function, a lower risk of endocarditis, a lower risk of thrombo-embolic complications, less use of lifelong anticoagulation, and lower costs [38, 39].
In recent years mitral valve repair for significant MR due to LS endocarditis has been described in 10 patients (Table 2) [16, 23, 24, 4045]. Unfortunately the exact surgical repair techniques were not described in 4 of these patients [16, 42, 44, 45]. In this report we added two mitral valve repair cases to the literature with a precise description of mitral valve pathology and mitral valve repair techniques. In both patients (one with SLE and one with primary APS) intraoperative macroscopic examination revealed only localized abnormalities with otherwise relatively normal leaflets. Therefore mitral valve repair was considered a good surgical option in these two patients. Echocardiographic and clinical follow-up of both patients after 11 and 1.5 years, respectively, showed excellent results and no recurrence of MR. To our knowledge, this is the longest follow-up ever described after mitral valve repair for MR caused by LS endocarditis.
Some studies suggest that results of mitral valve replacement (MVR) are usually superior to repair for LS endocarditis [41, 42]. According to these studies, severe (ongoing) calcification and fibrosis lead to rapid recurrence of MR after repair with a subsequent reoperation and MVR [41, 42]. In our systematic review we found two cases of MVR after initial repair for MR due to LS endocarditis [41, 42]. In the first case severe mitral stenosis developed 6 months after mitral valve repair due to ongoing calcification [41] and in the second case severe MR recurred 29 months after repair [42].
Taken together, we believe mitral valve repair for LS endocarditis of the mitral valve can be justified in specific patients. If SLE and/or APS has been relatively stable (with immunosuppresive therapy) in a young patient, if intraoperative macroscopic examination reveals relatively normal leaflets with only localized abnormalities, and if repair seems feasible, then mitral valve repair is in our opinion certainly justified and probably the preferred surgical option. Especially in young females, who are likely to become pregnant in the near future, long-term anticoagulation is preferably avoided by mitral valve repair. However, as previously mentioned, anticoagulation is often still necessary in LS endocarditis and APS to prevent future thrombo-embolic events. In that case mitral valve replacement with preservation of the subvalvular apparatus may be a good surgical alternative.
In case of mitral valve replacement, prosthetic valve selection is highly individualized based on age and other factors. In patients with bleeding abnormalities the superiority of bioprosthetic valves over mechanical valves is clear. However, mechanical valve replacement is recommended in patients at low risk with anticoagulation and at high risk for bioprosthetic valve calcification. Although succesful placement of porcine bioprostheses in patients with LS endocarditis has been reported (Table 2), complications can arise. In our systematic review we found one case in which a bioprosthetic porcine valve had to be replaced, because it was affected by (rapid) calcification and valvulitis and subsequent perforation [46] and another case in which massive bioprosthetic thrombosis occurred [47]. Again stressing the importance of anticoagulation in this disease. In addition, (SLE associated) renal failure can accelerate bioprosthetic degeneration as a consequence of abnormal calcium and phosphate metabolism [40]. Therefore, a mechanical prosthesis may provide better results than a bioprosthesis for MR caused by LS endocarditis, even though mechanical prostheses carry a higher risk of thrombo-embolic complications.
Evidently, no definite consensus has been reached at this point as to whether or not these valves should be replaced or repaired and whether a mechanical prosthesis is more advantageous than a bioprosthesis.

Conclusion

LS endocarditis should be strongly suspected when significant valve dysfunction, such as MR, develops during the course of SLE and/or APS. Differentiation from infective endocarditis and intracardiac tumors can be difficult, but is important and has different therapeutic implications. After establishing the diagnosis, periodic echocardiographic follow-up is recommended to detect detoriation of valvular function. When severe symptomatic MR requires surgery, mitral valve repair should always be considered. This report showed that mitral valve repair is feasible and effective in young patients with relatively stable SLE and/or APS and only localized mitral valve abnormalities caused by LS endocarditis. Both clinical and echocardiographic follow-up showed excellent mid- and long-term results.

Acknowledgements

The authors wish to express their gratitude to J.J. Meuzelaar for reviewing the article, to H.M. Willemsen for assistance with echocardiographic image acquisition, and to H.J. Buikema for assistance with histopathological image acquisition. This study was financially supported by University Medical Center Groningen and the Groningen University Institute for Drug Exploration.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

WB collected the data, systematically reviewed the literature, and wrote the manuscript. TK was lead surgeon. TK, IH, IJH, ME, MB, AS, FZ, and MM participated in the design of the manuscript and they revised and critically reviewed the manuscript. All authors read and approved the final manuscript.
Anhänge

Authors’ original submitted files for images

Literatur
1.
Zurück zum Zitat Libman E, Sacks B: A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924, 33: 701-37.CrossRef Libman E, Sacks B: A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924, 33: 701-37.CrossRef
2.
Zurück zum Zitat Gross L: The cardiac lesions in Libman-Sacks disease with a consideration of its relationship to acute diffuse lupus erythematosus. Am J Pathol. 1940, 16: 375-407.PubMedPubMedCentral Gross L: The cardiac lesions in Libman-Sacks disease with a consideration of its relationship to acute diffuse lupus erythematosus. Am J Pathol. 1940, 16: 375-407.PubMedPubMedCentral
3.
Zurück zum Zitat D'Alton JG, Preston DN, Bormanis J, Green MS, Kraag GR: Multiple transient ischemic attacks, lupus anticoagulant and verrucous endocarditis. Stroke. 1985, 16: 512-4.CrossRefPubMed D'Alton JG, Preston DN, Bormanis J, Green MS, Kraag GR: Multiple transient ischemic attacks, lupus anticoagulant and verrucous endocarditis. Stroke. 1985, 16: 512-4.CrossRefPubMed
4.
Zurück zum Zitat Cervera R, Khamashta MA, Font J, Reyes PA, Vianna JL, López-Soto A, Amigo MC, Asherson RA, Azqueta M, Paré C, Vargas J, Romero A, Ingelmo M, Hughes GRV: High prevalence of significant heart valve lesions in patients with the "primary" antiphospholipid syndrome. Lupus. 1991, 1: 43-7. 10.1177/096120339100100108.CrossRefPubMed Cervera R, Khamashta MA, Font J, Reyes PA, Vianna JL, López-Soto A, Amigo MC, Asherson RA, Azqueta M, Paré C, Vargas J, Romero A, Ingelmo M, Hughes GRV: High prevalence of significant heart valve lesions in patients with the "primary" antiphospholipid syndrome. Lupus. 1991, 1: 43-7. 10.1177/096120339100100108.CrossRefPubMed
5.
Zurück zum Zitat Hojnik M, George J, Ziporen L, Shoenfeld Y: Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996, 93: 1579-87.CrossRefPubMed Hojnik M, George J, Ziporen L, Shoenfeld Y: Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996, 93: 1579-87.CrossRefPubMed
6.
Zurück zum Zitat Doherty NE, Siegel RJ: Cardiovascular manifestations of systemic lupus eryhematosus. Am Heart J. 1985, 110: 1257-65. 10.1016/0002-8703(85)90023-7.CrossRefPubMed Doherty NE, Siegel RJ: Cardiovascular manifestations of systemic lupus eryhematosus. Am Heart J. 1985, 110: 1257-65. 10.1016/0002-8703(85)90023-7.CrossRefPubMed
7.
Zurück zum Zitat Ansari A, Larson PH, Bates HD: Cardiovascular manifestations of systemic lupus erythematosus: current perspective. Prog Cardiovasc Dis. 1985, 27: 421-34. 10.1016/0033-0620(85)90003-9.CrossRefPubMed Ansari A, Larson PH, Bates HD: Cardiovascular manifestations of systemic lupus erythematosus: current perspective. Prog Cardiovasc Dis. 1985, 27: 421-34. 10.1016/0033-0620(85)90003-9.CrossRefPubMed
8.
Zurück zum Zitat Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM: Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007, 120: 636-42. 10.1016/j.amjmed.2007.01.024.CrossRefPubMed Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM: Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007, 120: 636-42. 10.1016/j.amjmed.2007.01.024.CrossRefPubMed
9.
Zurück zum Zitat Roldan CA, Shively BK, Lau CC, Gurule FT, Smith EA, Crawford MH: Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol. 1992, 20: 1127-34.CrossRefPubMed Roldan CA, Shively BK, Lau CC, Gurule FT, Smith EA, Crawford MH: Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol. 1992, 20: 1127-34.CrossRefPubMed
10.
Zurück zum Zitat Roldan CA, Shively BK, Crawford MH: An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996, 335: 1424-30. 10.1056/NEJM199611073351903.CrossRefPubMed Roldan CA, Shively BK, Crawford MH: An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996, 335: 1424-30. 10.1056/NEJM199611073351903.CrossRefPubMed
11.
Zurück zum Zitat Hughes GR, Harris NN, Gharavi AE: The anticardiolipin syndrome. J Rheumatol. 1986, 13: 486-9.PubMed Hughes GR, Harris NN, Gharavi AE: The anticardiolipin syndrome. J Rheumatol. 1986, 13: 486-9.PubMed
12.
Zurück zum Zitat Harris EN: A reassessment of the antiphospholipid syndrome. J Rheumatol. 1990, 17: 733-5.PubMed Harris EN: A reassessment of the antiphospholipid syndrome. J Rheumatol. 1990, 17: 733-5.PubMed
13.
Zurück zum Zitat Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med. 2002, 346: 752-63. 10.1056/NEJMra002974.CrossRefPubMed Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med. 2002, 346: 752-63. 10.1056/NEJMra002974.CrossRefPubMed
14.
Zurück zum Zitat Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Artritis Rheum. 1999, 42: 1309-11. 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F.CrossRef Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Artritis Rheum. 1999, 42: 1309-11. 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F.CrossRef
15.
Zurück zum Zitat Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ, Vázquez JJ, Paré C, Ingelmo M, Oliver J, Hughes GR: Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet. 1990, 335: 1541-4. 10.1016/0140-6736(90)91373-I.CrossRefPubMed Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ, Vázquez JJ, Paré C, Ingelmo M, Oliver J, Hughes GR: Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet. 1990, 335: 1541-4. 10.1016/0140-6736(90)91373-I.CrossRefPubMed
16.
Zurück zum Zitat Takayama T, Teramura M, Sakai H, Tamaki S, Okabayashi T, Kawashima T, Yamamoto T, Horie M, Suzuki T, Asai T: Perforated mitral valve aneurysm associated with Libman-Sacks endocarditis. Inter Med. 2008, 47: 1605-8. 10.2169/internalmedicine.47.1068.CrossRef Takayama T, Teramura M, Sakai H, Tamaki S, Okabayashi T, Kawashima T, Yamamoto T, Horie M, Suzuki T, Asai T: Perforated mitral valve aneurysm associated with Libman-Sacks endocarditis. Inter Med. 2008, 47: 1605-8. 10.2169/internalmedicine.47.1068.CrossRef
17.
Zurück zum Zitat Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD: Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med. 1989, 86: 407-12. 10.1016/0002-9343(89)90337-9.CrossRefPubMed Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD: Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med. 1989, 86: 407-12. 10.1016/0002-9343(89)90337-9.CrossRefPubMed
18.
Zurück zum Zitat Ford SE, Charrette EJ, Knight J, Pym J, Ford P: A possible role for antiphospholipid antibodies in acquired cardiac valve deformity. J Rheumatol. 1990, 17: 1499-503.PubMed Ford SE, Charrette EJ, Knight J, Pym J, Ford P: A possible role for antiphospholipid antibodies in acquired cardiac valve deformity. J Rheumatol. 1990, 17: 1499-503.PubMed
19.
Zurück zum Zitat Ziporen L, Goldberg I, Arad M, Hojnik M, Ordi-Ros J, Afek A, Blank M, Sandbank Y, Vilardell-Tarres M, de Torres I, Weinberger A, Asherson RA, Kopolovic Y, Shoenfeld Y: Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996, 5: 196-205. 10.1177/096120339600500306.CrossRefPubMed Ziporen L, Goldberg I, Arad M, Hojnik M, Ordi-Ros J, Afek A, Blank M, Sandbank Y, Vilardell-Tarres M, de Torres I, Weinberger A, Asherson RA, Kopolovic Y, Shoenfeld Y: Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996, 5: 196-205. 10.1177/096120339600500306.CrossRefPubMed
20.
Zurück zum Zitat Gleason CB, Stoddard MF, Wagner SG, Longaker RA, Pierangeli S, Harris EN: A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus. Am Heart J. 1993, 125: 1123-9. 10.1016/0002-8703(93)90124-R.CrossRefPubMed Gleason CB, Stoddard MF, Wagner SG, Longaker RA, Pierangeli S, Harris EN: A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus. Am Heart J. 1993, 125: 1123-9. 10.1016/0002-8703(93)90124-R.CrossRefPubMed
21.
Zurück zum Zitat Asherson RA, Cervera R: Antiphospholipid antibodies and the heart. Lessons and pitfalls for the cardiologist. Circulation. 1991, 84: 920-3.CrossRefPubMed Asherson RA, Cervera R: Antiphospholipid antibodies and the heart. Lessons and pitfalls for the cardiologist. Circulation. 1991, 84: 920-3.CrossRefPubMed
22.
Zurück zum Zitat Asopa S, Patel A, Khan OA, Sharma R, Ohri SK: Non-bacterial thrombotic endocarditis. Eur J Cardiothorac Surg. 2007, 32: 696-701. 10.1016/j.ejcts.2007.07.029.CrossRefPubMed Asopa S, Patel A, Khan OA, Sharma R, Ohri SK: Non-bacterial thrombotic endocarditis. Eur J Cardiothorac Surg. 2007, 32: 696-701. 10.1016/j.ejcts.2007.07.029.CrossRefPubMed
23.
Zurück zum Zitat Mottram PM, Gelman JS: Mitral valve thrombus mimicking a primary tumor in the antiphospholipid syndrome. J Am Soc Echocardiogr. 2002, 15: 746-8. 10.1067/mje.2002.118914.CrossRefPubMed Mottram PM, Gelman JS: Mitral valve thrombus mimicking a primary tumor in the antiphospholipid syndrome. J Am Soc Echocardiogr. 2002, 15: 746-8. 10.1067/mje.2002.118914.CrossRefPubMed
24.
Zurück zum Zitat Taguchi S, Hashimoto K, Sakamoto Y, Okuyama H, Ishii S: A case of mitral valve plasty for Libman-Sacks endocarditis mimicking a cardiac tumor. J Thorac Cardiovasc Surg. 2006, 132: 1465-7. 10.1016/j.jtcvs.2006.07.034.CrossRefPubMed Taguchi S, Hashimoto K, Sakamoto Y, Okuyama H, Ishii S: A case of mitral valve plasty for Libman-Sacks endocarditis mimicking a cardiac tumor. J Thorac Cardiovasc Surg. 2006, 132: 1465-7. 10.1016/j.jtcvs.2006.07.034.CrossRefPubMed
25.
Zurück zum Zitat Appelbe AF, Olson D, Mixon R, Craver JM, Martin RP: Libman-Sacks endocarditis mimicking intracardiac tumor. Am J Cardiol. 1991, 68: 817-8. 10.1016/0002-9149(91)90666-9.CrossRefPubMed Appelbe AF, Olson D, Mixon R, Craver JM, Martin RP: Libman-Sacks endocarditis mimicking intracardiac tumor. Am J Cardiol. 1991, 68: 817-8. 10.1016/0002-9149(91)90666-9.CrossRefPubMed
26.
Zurück zum Zitat Lee JL, Naguwa SM, Cheema GS, Gershwin ME: Revisiting Libman-Sacks endocarditis: a historical review and update. Clin Rev Allergy Immunol. 2009, 36: 126-30. 10.1007/s12016-008-8113-y.CrossRefPubMed Lee JL, Naguwa SM, Cheema GS, Gershwin ME: Revisiting Libman-Sacks endocarditis: a historical review and update. Clin Rev Allergy Immunol. 2009, 36: 126-30. 10.1007/s12016-008-8113-y.CrossRefPubMed
27.
Zurück zum Zitat Lehman TJ, Palmeri ST, Hastings C, Klippel JH, Plotz PH: Bacterial endocarditis complicating systemic lupus erythematosus. J Rheumatol. 1983, 10: 655-8.PubMed Lehman TJ, Palmeri ST, Hastings C, Klippel JH, Plotz PH: Bacterial endocarditis complicating systemic lupus erythematosus. J Rheumatol. 1983, 10: 655-8.PubMed
28.
Zurück zum Zitat Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, Bashore T, Corey GR: Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000, 30: 633-8. 10.1086/313753.CrossRefPubMed Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, Bashore T, Corey GR: Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000, 30: 633-8. 10.1086/313753.CrossRefPubMed
29.
Zurück zum Zitat Ménard GE: Establishing the diagnosis of Libman-Sacks endocarditis in systemic lupus erythematosus. J Gen Intern Med. 2008, 23: 883-6. 10.1007/s11606-008-0627-8.CrossRefPubMedPubMedCentral Ménard GE: Establishing the diagnosis of Libman-Sacks endocarditis in systemic lupus erythematosus. J Gen Intern Med. 2008, 23: 883-6. 10.1007/s11606-008-0627-8.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Feigenbaum H, Armstrong WF, Ryan T: Feigenbaum's Echocardiography. 2005, Philadelphia: Lippincott Williams and Wilkins, 375-81. Feigenbaum H, Armstrong WF, Ryan T: Feigenbaum's Echocardiography. 2005, Philadelphia: Lippincott Williams and Wilkins, 375-81.
31.
Zurück zum Zitat Klarich KW, Enriquez-Sarano M, Gura GM, Edwards WD, Tajik AJ, Seward JB: Papillary firboelastoma: echocardiographic characteristics for diagnosis and pathologic correlation. J Am Coll Cardiol. 1997, 30: 784-90. 10.1016/S0735-1097(97)00211-8.CrossRefPubMed Klarich KW, Enriquez-Sarano M, Gura GM, Edwards WD, Tajik AJ, Seward JB: Papillary firboelastoma: echocardiographic characteristics for diagnosis and pathologic correlation. J Am Coll Cardiol. 1997, 30: 784-90. 10.1016/S0735-1097(97)00211-8.CrossRefPubMed
32.
Zurück zum Zitat Roldan CA, Qualls CR, Sopko KS, Sibbitt WL: Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J Rheumatol. 2008, 35: 224-9.PubMed Roldan CA, Qualls CR, Sopko KS, Sibbitt WL: Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J Rheumatol. 2008, 35: 224-9.PubMed
33.
Zurück zum Zitat Morin AM, Boyer AS, Nataf P, Gandjbakhch I: Mitral insufficiency caused by systemic lupus erythematosus requiring valve replacement: three case reports and a review of the literature. Thorac Cardiovasc Surg. 1996, 44: 313-6. 10.1055/s-2007-1012045.CrossRefPubMed Morin AM, Boyer AS, Nataf P, Gandjbakhch I: Mitral insufficiency caused by systemic lupus erythematosus requiring valve replacement: three case reports and a review of the literature. Thorac Cardiovasc Surg. 1996, 44: 313-6. 10.1055/s-2007-1012045.CrossRefPubMed
34.
Zurück zum Zitat Bulkey BH, Roberts WC: Systemic lupus erythematosus as a cause of severe mitral regurgitation. New problem in an old disease. Am J Cardiol. 1975, 35: 305-8. 10.1016/0002-9149(75)90018-1.CrossRefPubMed Bulkey BH, Roberts WC: Systemic lupus erythematosus as a cause of severe mitral regurgitation. New problem in an old disease. Am J Cardiol. 1975, 35: 305-8. 10.1016/0002-9149(75)90018-1.CrossRefPubMed
35.
Zurück zum Zitat Hoffman R, Lethen H, Zunker U, Schöndube FA, Maurin N, Sieberth HG: Rapid appearance of severe mitral regurgitation under high-dosage corticosteroid therapy in a patient with systemic lupus erythematosus. Eur Heart J. 1994, 15: 138-9.PubMed Hoffman R, Lethen H, Zunker U, Schöndube FA, Maurin N, Sieberth HG: Rapid appearance of severe mitral regurgitation under high-dosage corticosteroid therapy in a patient with systemic lupus erythematosus. Eur Heart J. 1994, 15: 138-9.PubMed
36.
Zurück zum Zitat Gonzalez-Juanatey C, Gonzalez-Gay MA: Libman-Sacks endocarditis and primary antiphospholipid syndrome. J Heart Valve Dis. 2005, 14: 700-2.PubMed Gonzalez-Juanatey C, Gonzalez-Gay MA: Libman-Sacks endocarditis and primary antiphospholipid syndrome. J Heart Valve Dis. 2005, 14: 700-2.PubMed
37.
Zurück zum Zitat Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008, 29: 2388-442. 10.1093/eurheartj/ehn309.CrossRefPubMed Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008, 29: 2388-442. 10.1093/eurheartj/ehn309.CrossRefPubMed
38.
Zurück zum Zitat Yun KL, Miller DC: Mitral valve repair versus replacement. Cardiol Clin. 1991, 9: 315-27.PubMed Yun KL, Miller DC: Mitral valve repair versus replacement. Cardiol Clin. 1991, 9: 315-27.PubMed
39.
Zurück zum Zitat Gillinov AM, Cosgrove DM: Current status of mitral valve repair. Am Heart Hosp J. 2003, 1: 47-54. 10.1111/j.1541-9215.2003.02082.x.CrossRefPubMed Gillinov AM, Cosgrove DM: Current status of mitral valve repair. Am Heart Hosp J. 2003, 1: 47-54. 10.1111/j.1541-9215.2003.02082.x.CrossRefPubMed
40.
Zurück zum Zitat Kalangos A, Panos A, Sezerman O: Mitral valve repair in lupus valvulitis - report of a case and review of the literature. J Heart Valve Dis. 1995, 4: 202-7.PubMed Kalangos A, Panos A, Sezerman O: Mitral valve repair in lupus valvulitis - report of a case and review of the literature. J Heart Valve Dis. 1995, 4: 202-7.PubMed
41.
Zurück zum Zitat Chauvaud SM, Kalangos A, Berrebi AJ, Gaer AR, Acar C, Carpentier AF: Systemic lupus erythematosus valvulitis: mitral valve replacement with a homograft. Ann Thorac Surg. 1995, 60: 1803-5. 10.1016/0003-4975(95)00625-7.CrossRefPubMed Chauvaud SM, Kalangos A, Berrebi AJ, Gaer AR, Acar C, Carpentier AF: Systemic lupus erythematosus valvulitis: mitral valve replacement with a homograft. Ann Thorac Surg. 1995, 60: 1803-5. 10.1016/0003-4975(95)00625-7.CrossRefPubMed
42.
Zurück zum Zitat Hakim JP, Mehta A, Jain AC, Murray GF: Mitral valve replacement and repair. Report of 5 patients with systemic lupus erythematosus. Tex Heart Inst J. 2001, 28: 47-52.PubMedPubMedCentral Hakim JP, Mehta A, Jain AC, Murray GF: Mitral valve replacement and repair. Report of 5 patients with systemic lupus erythematosus. Tex Heart Inst J. 2001, 28: 47-52.PubMedPubMedCentral
43.
Zurück zum Zitat Kato Y, Isobe F, Sasaki Y, Kodera K, Kumano H, Nagamachi K: Mitral insufficiency associated with primary antiphospholipid syndrome and chronic renal failure. Jpn J Thorac Cardiovasc Surg. 2001, 49: 171-4. 10.1007/BF02913596.CrossRefPubMed Kato Y, Isobe F, Sasaki Y, Kodera K, Kumano H, Nagamachi K: Mitral insufficiency associated with primary antiphospholipid syndrome and chronic renal failure. Jpn J Thorac Cardiovasc Surg. 2001, 49: 171-4. 10.1007/BF02913596.CrossRefPubMed
44.
Zurück zum Zitat Schneider C, Bahlmann E, Antz M, Bauer R, Reimers J, Raut W, Busch C, Rathjen F, Moll R, Kuck KH: Images in cardiovascular medicine. Unusual manifestation of Libman-Sacks endocarditis in systemic lupus erythematosus. Circulation. 2003, 107: e202-4. 10.1161/01.CIR.0000063926.32375.D3.CrossRefPubMed Schneider C, Bahlmann E, Antz M, Bauer R, Reimers J, Raut W, Busch C, Rathjen F, Moll R, Kuck KH: Images in cardiovascular medicine. Unusual manifestation of Libman-Sacks endocarditis in systemic lupus erythematosus. Circulation. 2003, 107: e202-4. 10.1161/01.CIR.0000063926.32375.D3.CrossRefPubMed
45.
Zurück zum Zitat Fernández-Dueñas J, López-Granados A, Mesa-Rubio D, Ariz-Cañete J, Gallo-Marín M, Concha-Ruiz M: Severe mitral regurgitation in Libman-Sacks endocarditis. Conservative surgery. Rev Esp Cardiol. 2005, 58: 1118-20. 10.1157/13078558.CrossRefPubMed Fernández-Dueñas J, López-Granados A, Mesa-Rubio D, Ariz-Cañete J, Gallo-Marín M, Concha-Ruiz M: Severe mitral regurgitation in Libman-Sacks endocarditis. Conservative surgery. Rev Esp Cardiol. 2005, 58: 1118-20. 10.1157/13078558.CrossRefPubMed
46.
Zurück zum Zitat Gordon RJ, Weilbaecher D, Davy SM, Safi HJ, Quiñones MA, DeFelice CA, Zoghbi WA: Valvulitis involving a bioprosthetic valve in a patient with systematic lupus erythematosus. J Am Soc Echocardiogr. 1996, 9: 104-7. 10.1016/S0894-7317(96)90112-1.CrossRefPubMed Gordon RJ, Weilbaecher D, Davy SM, Safi HJ, Quiñones MA, DeFelice CA, Zoghbi WA: Valvulitis involving a bioprosthetic valve in a patient with systematic lupus erythematosus. J Am Soc Echocardiogr. 1996, 9: 104-7. 10.1016/S0894-7317(96)90112-1.CrossRefPubMed
47.
Zurück zum Zitat Da Silva AN, Ferreira LD, Monaco CG, Silva CE, Gil MA, Peixoto LB, Ortiz J: Intracardiac thrombus and mitral prosthesis dysfunction in systemic lupus erythematosus. A case report. Rev Port Cardiol. 2003, 22: 213-9.PubMed Da Silva AN, Ferreira LD, Monaco CG, Silva CE, Gil MA, Peixoto LB, Ortiz J: Intracardiac thrombus and mitral prosthesis dysfunction in systemic lupus erythematosus. A case report. Rev Port Cardiol. 2003, 22: 213-9.PubMed
48.
Zurück zum Zitat Myerowitz PD, Michaelis LL, McIntosh CL: Mitral valve replacement for mitral regurgitation due to Libman-Sacks endocarditis. Report of a case. J Thorac Cardiovasc Surg. 1974, 67: 869-74.PubMed Myerowitz PD, Michaelis LL, McIntosh CL: Mitral valve replacement for mitral regurgitation due to Libman-Sacks endocarditis. Report of a case. J Thorac Cardiovasc Surg. 1974, 67: 869-74.PubMed
49.
Zurück zum Zitat Murray FT, Fuleihan DS, Cornwall CS, Pinals RS: Acute mitral regurgitation from ruptured chordae tendineae in systemic lupus erythematosus. J Rheumatol. 1975, 2: 454-9.PubMed Murray FT, Fuleihan DS, Cornwall CS, Pinals RS: Acute mitral regurgitation from ruptured chordae tendineae in systemic lupus erythematosus. J Rheumatol. 1975, 2: 454-9.PubMed
50.
Zurück zum Zitat Paget SA, Bulkley BH, Grauer LE, Seningen R: Mitral valve disease of systemic lupus erythematosus. A cause of severe congestive heart failure reversed by valve replacement. Am J Med. 1975, 59: 134-9. 10.1016/0002-9343(75)90331-9.CrossRefPubMed Paget SA, Bulkley BH, Grauer LE, Seningen R: Mitral valve disease of systemic lupus erythematosus. A cause of severe congestive heart failure reversed by valve replacement. Am J Med. 1975, 59: 134-9. 10.1016/0002-9343(75)90331-9.CrossRefPubMed
51.
Zurück zum Zitat Kinney EL, Wynn J, Ward S, Babb JD, Wine-Shaffer C, Zelis R: Ruptured chordae tendineae. Its association with systemic lupus erythematosus. Arch Pathol Lab Med. 1980, 104: 595-6.PubMed Kinney EL, Wynn J, Ward S, Babb JD, Wine-Shaffer C, Zelis R: Ruptured chordae tendineae. Its association with systemic lupus erythematosus. Arch Pathol Lab Med. 1980, 104: 595-6.PubMed
52.
Zurück zum Zitat Rawsthorne L, Ptacin MJ, Choi H, Olinger GN, Bamrah VS: Lupus valvulitis necessitating double valve replacement. Arthritis Rheum. 1981, 24: 561-4. 10.1002/art.1780240319.CrossRefPubMed Rawsthorne L, Ptacin MJ, Choi H, Olinger GN, Bamrah VS: Lupus valvulitis necessitating double valve replacement. Arthritis Rheum. 1981, 24: 561-4. 10.1002/art.1780240319.CrossRefPubMed
53.
Zurück zum Zitat Brennan FJ, Ford SE, Ford PM, Morrin PA, Burggraf GW, Salerno TA: Mitral regurgitation due to lupus endocarditis treated with valve replacement. Can Med Assoc J. 1983, 129: 584-7.PubMedPubMedCentral Brennan FJ, Ford SE, Ford PM, Morrin PA, Burggraf GW, Salerno TA: Mitral regurgitation due to lupus endocarditis treated with valve replacement. Can Med Assoc J. 1983, 129: 584-7.PubMedPubMedCentral
54.
Zurück zum Zitat Rozman B, Radovanovic N, Zorc M, Vraspir-Porenta O, Cijan A, Zemva A: Mitral valve replacement for lupus valvulitis. Z Rheumatol. 1986, 45: 322-4.PubMed Rozman B, Radovanovic N, Zorc M, Vraspir-Porenta O, Cijan A, Zemva A: Mitral valve replacement for lupus valvulitis. Z Rheumatol. 1986, 45: 322-4.PubMed
55.
Zurück zum Zitat Moynihan T, Hansen R, Troup P, Olinger G: Simultaneous aortic and mitral valve replacement for lupus endocarditis: report of a case and review of the literature. J Thorac Cardiovasc Surg. 1988, 95: 142-5.PubMed Moynihan T, Hansen R, Troup P, Olinger G: Simultaneous aortic and mitral valve replacement for lupus endocarditis: report of a case and review of the literature. J Thorac Cardiovasc Surg. 1988, 95: 142-5.PubMed
56.
Zurück zum Zitat Straaton KV, Chatham WW, Reveille JD, Koopman WJ, Smith SH: Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med. 1988, 85: 645-50. 10.1016/S0002-9343(88)80236-5.CrossRefPubMed Straaton KV, Chatham WW, Reveille JD, Koopman WJ, Smith SH: Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med. 1988, 85: 645-50. 10.1016/S0002-9343(88)80236-5.CrossRefPubMed
57.
Zurück zum Zitat Ferraris VA, Hawksley VC, Rabinowitz M, Coyne CM, Sullivan TJ, Sprague MS: Double valve replacement for lupus valvulitis: report of a case and review of the literature. Tex Heart Inst J. 1990, 17: 56-60.PubMedPubMedCentral Ferraris VA, Hawksley VC, Rabinowitz M, Coyne CM, Sullivan TJ, Sprague MS: Double valve replacement for lupus valvulitis: report of a case and review of the literature. Tex Heart Inst J. 1990, 17: 56-60.PubMedPubMedCentral
58.
Zurück zum Zitat Alvarez-Blanco A, Egurbide-Arberas MV, Aguirre-Errasti C: Severe valvular heart disease in a patient with primary antiphospholipid syndrome. Lupus. 1994, 3: 433-4.PubMed Alvarez-Blanco A, Egurbide-Arberas MV, Aguirre-Errasti C: Severe valvular heart disease in a patient with primary antiphospholipid syndrome. Lupus. 1994, 3: 433-4.PubMed
59.
Zurück zum Zitat Shahian DM, Labib SB, Schneebaum AB: Etiology and management of chronic valve disease in antiphospholipid antibody syndrome and systemic lupus erythematosus. J Card Surg. 1995, 10: 133-9.CrossRefPubMed Shahian DM, Labib SB, Schneebaum AB: Etiology and management of chronic valve disease in antiphospholipid antibody syndrome and systemic lupus erythematosus. J Card Surg. 1995, 10: 133-9.CrossRefPubMed
60.
Zurück zum Zitat East CJ, Clements F, Mathew J, Slaughter TF: Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth Analg. 2000, 90: 1098-101. 10.1097/00000539-200005000-00017.CrossRefPubMed East CJ, Clements F, Mathew J, Slaughter TF: Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth Analg. 2000, 90: 1098-101. 10.1097/00000539-200005000-00017.CrossRefPubMed
61.
Zurück zum Zitat Georghiou GP, Shapira Y, Drozd T, Erez E, Raanani E, Vidne BA, Sahar G: Double-valve Libman-Sacks endocarditis: an entity that demands special consideration. J Heart Valve Dis. 2003, 12: 797-801.PubMed Georghiou GP, Shapira Y, Drozd T, Erez E, Raanani E, Vidne BA, Sahar G: Double-valve Libman-Sacks endocarditis: an entity that demands special consideration. J Heart Valve Dis. 2003, 12: 797-801.PubMed
62.
Zurück zum Zitat Bordin G, Boldorini R, Meroni PL: The two hit hypothesis in the antiphospholipid syndrome: acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS. Lupus. 2003, 12: 851-3. 10.1191/0961203303lu445cr.CrossRefPubMed Bordin G, Boldorini R, Meroni PL: The two hit hypothesis in the antiphospholipid syndrome: acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS. Lupus. 2003, 12: 851-3. 10.1191/0961203303lu445cr.CrossRefPubMed
63.
Zurück zum Zitat Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y: Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004, 127: 414-20. 10.1016/j.jtcvs.2003.07.016.CrossRefPubMed Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y: Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004, 127: 414-20. 10.1016/j.jtcvs.2003.07.016.CrossRefPubMed
64.
Zurück zum Zitat Einav E, Gitig A, Marinescu LM, Tanaka KE, Spevack DM: Valvulitis requiring triple valve surgery as an initial presentation of systemic lupus erythematosus. J Am Soc Echocardiogr. 2007, 20: e1-3.CrossRef Einav E, Gitig A, Marinescu LM, Tanaka KE, Spevack DM: Valvulitis requiring triple valve surgery as an initial presentation of systemic lupus erythematosus. J Am Soc Echocardiogr. 2007, 20: e1-3.CrossRef
Metadaten
Titel
Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature
verfasst von
Wobbe Bouma
Theo J Klinkenberg
Iwan CC van der Horst
Inez J Wijdh-den Hamer
Michiel E Erasmus
Marc Bijl
Albert JH Suurmeijer
Felix Zijlstra
Massimo A Mariani
Publikationsdatum
01.12.2010
Verlag
BioMed Central
Erschienen in
Journal of Cardiothoracic Surgery / Ausgabe 1/2010
Elektronische ISSN: 1749-8090
DOI
https://doi.org/10.1186/1749-8090-5-13

Weitere Artikel der Ausgabe 1/2010

Journal of Cardiothoracic Surgery 1/2010 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.